APA (7th ed.) Citation

Yuan, Y., Deng, Y., Jin, Y., Guo, Z., Pan, Y., Wang, C., . . . Ding, K. Efficacy and safety of IBI351 (fulzerasib) monotherapy in KRASG12C inhibitor-naïve Chinese patients with KRAS G12C-mutated metastatic colorectal cancer: A pooled analysis from phase I part of two studies. Nature Publishing Group.

Chicago Style (17th ed.) Citation

Yuan, Ying, et al. Efficacy and Safety of IBI351 (fulzerasib) Monotherapy in KRASG12C Inhibitor-naïve Chinese Patients with KRAS G12C-mutated Metastatic Colorectal Cancer: A Pooled Analysis from Phase I Part of Two Studies. Nature Publishing Group.

MLA (9th ed.) Citation

Yuan, Ying, et al. Efficacy and Safety of IBI351 (fulzerasib) Monotherapy in KRASG12C Inhibitor-naïve Chinese Patients with KRAS G12C-mutated Metastatic Colorectal Cancer: A Pooled Analysis from Phase I Part of Two Studies. Nature Publishing Group.